Now I'll synthesize the comprehensive reference document from medical library findings and expert clinical knowledge:
π₯ 20 Hormonal (Endocrine) Diseases β Comprehensive Clinical Reference
All Age Groups | Treatment | Investigations | Findings | DDx | ICU/OPD | CBC | Nutrition
π MASTER OVERVIEW TABLE
| # | Disease | Gland/Hormone | Age Group Most Affected | Setting |
|---|
| 1 | Type 1 Diabetes Mellitus | Pancreas / Insulin β | Children, Young Adults | OPD/ICU |
| 2 | Type 2 Diabetes Mellitus | Pancreas / Insulin resistance | Adults >40, Obese | OPD |
| 3 | Hypothyroidism | Thyroid / T3,T4 β | All ages (F>M) | OPD |
| 4 | Hyperthyroidism / Graves' | Thyroid / T3,T4 β | Young-Middle-aged F | OPD/ICU |
| 5 | Cushing's Syndrome | Adrenal / Cortisol β | Adults 20β50 | OPD/ICU |
| 6 | Addison's Disease | Adrenal / Cortisol β | Adults 30β50 | OPD/ICU |
| 7 | Congenital Hypothyroidism | Thyroid / T4 β | Neonates | NICU/OPD |
| 8 | Congenital Adrenal Hyperplasia (CAH) | Adrenal / Cortisol,Aldosterone β | Neonates, Infants | NICU/OPD |
| 9 | Diabetes Insipidus | Pituitary / ADH β | All ages | OPD/ICU |
| 10 | SIADH | Pituitary / ADH β | Adults, Elderly | ICU/OPD |
| 11 | Acromegaly | Pituitary / GH β | Adults 30β50 | OPD |
| 12 | Gigantism | Pituitary / GH β | Children/Adolescents | OPD |
| 13 | Pheochromocytoma | Adrenal medulla / Catecholamines β | Adults 30β50 | OPD/ICU |
| 14 | Primary Hyperaldosteronism (Conn's) | Adrenal / Aldosterone β | Adults 30β60 | OPD |
| 15 | Hypoparathyroidism | Parathyroid / PTH β | Adults, Post-surgical | OPD/ICU |
| 16 | Hyperparathyroidism | Parathyroid / PTH β | Adults >50, F>M | OPD |
| 17 | Polycystic Ovary Syndrome (PCOS) | Ovary / Androgens β, FSH/LH imbalance | Reproductive age F | OPD |
| 18 | Precocious Puberty | Gonads / Sex hormones β early | Children <8F, <9M | OPD |
| 19 | Growth Hormone Deficiency (GHD) | Pituitary / GH β | Children, Adults | OPD |
| 20 | Prolactinoma | Pituitary / Prolactin β | Young adults, F>M | OPD |
1οΈβ£ TYPE 1 DIABETES MELLITUS (T1DM)
Pathophysiology
Autoimmune destruction of pancreatic Ξ²-cells β absolute insulin deficiency β hyperglycemia, ketoacidosis
Age Group
Children (peak 5β7 y, 11β14 y), young adults; any age possible
Clinical Findings
- Classic triad: Polyuria, Polydipsia, Polyphagia + weight loss
- Diabetic Ketoacidosis (DKA): Kussmaul breathing, fruity breath, vomiting, altered consciousness
- Blurred vision, fatigue, recurrent infections
Investigations
| Test | Finding |
|---|
| Fasting plasma glucose | β₯126 mg/dL |
| 2-hr OGTT | β₯200 mg/dL |
| Random glucose | β₯200 mg/dL + symptoms |
| HbA1c | β₯6.5% |
| C-peptide | Very low/undetectable |
| Anti-GAD65, anti-IA2, anti-islet antibodies | Positive (confirm autoimmune) |
| Urinalysis | Glucose + ketones |
| Arterial blood gas (DKA) | Metabolic acidosis, pH <7.3 |
| Serum electrolytes | βKβΊ (total body deficit despite initial hyperkalemia) |
Blood Count (CBC)
- RBC: Normal or β (chronic disease anemia)
- WBC: β Leukocytosis in DKA (stress response/infection)
- Platelets: Usually normal; β (reactive thrombocytosis) in poor control
Treatment
| Setting | Regimen |
|---|
| OPD | Basal-bolus insulin (long-acting: glargine/detemir + rapid-acting: lispro/aspart), carb counting, CGM, HbA1c target <7% |
| ICU/DKA | IV regular insulin 0.1 U/kg/hr, IV fluids (0.9% NaCl), KβΊ replacement (add K if KβΊ <5.5 mEq/L), bicarb if pH <6.9 |
| Pediatric | Weight-based dosing; puberty increases insulin resistance |
Nutrition
- Carbohydrate counting (45β60g/meal adults)
- Low glycemic index foods; avoid concentrated sweets
- Regular meal timing; protein-adequate diet
Differential Diagnosis
- Type 2 DM (MODY), Maturity-Onset Diabetes of the Young (MODY)
- Pancreatogenic diabetes (Type 3c)
- DKA vs Hyperosmolar Hyperglycemic State (HHS)
- Drug-induced hyperglycemia (steroids)
Contraindications
- Metformin: contraindicated in T1DM as monotherapy
- Thiazolidinediones: not indicated in T1DM
- Sulfonylureas: avoid in T1DM
ICU Indications
DKA (pH <7.1, altered consciousness), severe hypoglycemia, sepsis
2οΈβ£ TYPE 2 DIABETES MELLITUS (T2DM)
Pathophysiology
Insulin resistance + progressive Ξ²-cell failure β relative insulin deficiency
Age Group
Adults >40 (increasingly adolescents/obese youth); gestational DM in pregnancy
Clinical Findings
- Often asymptomatic early; detected on screening
- Polyuria, polydipsia, fatigue, blurred vision, slow-healing wounds
- Acanthosis nigricans (insulin resistance skin sign)
- Hyperosmolar Hyperglycemic State (HHS): extreme hyperglycemia, dehydration, altered consciousness β no ketones
Investigations
Same glucose/HbA1c thresholds as T1DM, PLUS:
| Test | Finding |
|---|
| Fasting insulin / HOMA-IR | Elevated (insulin resistance) |
| C-peptide | Normal or elevated |
| Lipid panel | βTriglycerides, βHDL (metabolic syndrome) |
| Microalbuminuria | Early nephropathy marker |
| Serum creatinine/eGFR | Renal function assessment |
| Liver enzymes | Fatty liver (NAFLD common) |
Blood Count (CBC)
- RBC: β Normocytic anemia (CKD-related in advanced disease)
- WBC: Normal or mildly elevated
- Platelets: Often normal; β in obesity/inflammation
Treatment
| Step | Agent |
|---|
| First-line | Metformin + lifestyle modification |
| Add-on | GLP-1 agonists (semaglutide, liraglutide) β esp. with CVD/obesity |
| SGLT-2 inhibitors | (empagliflozin) β heart failure/CKD benefit |
| DPP-4 inhibitors | Sitagliptin β weight neutral |
| Sulfonylureas | Glipizide β low cost, risk of hypoglycemia |
| Insulin | Basal insulin if HbA1c >10% or symptomatic |
Nutrition
- Caloric deficit for weight loss (500β750 kcal/day deficit)
- Mediterranean or DASH diet preferred
- Fiber β₯25g/day; limit refined carbs, saturated fat, sugar-sweetened beverages
Differential Diagnosis
- T1DM (LADA β Latent Autoimmune Diabetes of Adults)
- MODY (monogenic; family history, young age)
- Cushing's syndrome (secondary DM)
- Acromegaly, glucagonoma
Contraindications
- Metformin: contraindicated if eGFR <30, severe liver disease, IV contrast (hold 48h), active alcoholism
- SGLT-2i: contraindicated if eGFR <20 (for glycemic purpose), T1DM (risk euDKA), recurrent UTI/genital infections
- GLP-1 agonists: contraindicated with personal/family history of medullary thyroid cancer/MEN2
3οΈβ£ HYPOTHYROIDISM
Pathophysiology
Insufficient thyroid hormone (T3/T4) β slowed metabolism
Age Group
- Congenital: Neonates (cretinism if untreated)
- Hashimoto's thyroiditis: Adolescents, adults (F>>M)
- Primary atrophic: Elderly
- Iatrogenic: Post-thyroidectomy, post-radioiodine
Clinical Findings
- Cold intolerance, weight gain, constipation, fatigue, depression
- Bradycardia, delayed tendon reflexes ("hung-up reflex")
- Dry skin, hair loss, periorbital puffiness (myxedema)
- Goiter (Hashimoto's), hoarse voice, macroglossia
- Myxedema coma (severe): hypothermia, hypotension, hypoventilation, coma
Investigations
| Test | Hypothyroidism Finding |
|---|
| TSH | βββ (primary); β (secondary/tertiary) |
| Free T4 | β |
| Free T3 | β |
| Anti-TPO antibodies | Positive (Hashimoto's) |
| Anti-thyroglobulin Ab | Positive (Hashimoto's) |
| Lipid panel | β Total cholesterol, β LDL |
| CK | β (myopathy) |
| NaβΊ | β (dilutional hyponatremia) |
| ECG | Bradycardia, low voltage, T-wave flattening |
Blood Count (CBC)
- RBC: β Macrocytic anemia (β EPO, B12/folate deficiency association), or normocytic
- WBC: Usually normal
- Platelets: May be β (thrombocytopenia, rare); β bleeding time
Treatment
| Setting | Treatment |
|---|
| OPD | Levothyroxine (T4): start 1.6 mcg/kg/day (lower dose in elderly/CAD); adjust by TSH every 6 weeks |
| Myxedema Coma (ICU) | IV levothyroxine 200β500 mcg bolus + IV T3 + IV hydrocortisone (until adrenal co-involvement excluded) + rewarming + respiratory support |
| Congenital | Levothyroxine ASAP (within 2 weeks of birth) |
| Pregnancy | Higher LT4 requirement; TSH target 0.1β2.5 mIU/L |
Nutrition
- Adequate iodine (iodized salt, seafood) unless Hashimoto's
- Selenium supplementation may help Hashimoto's
- Take levothyroxine 30β60 min before food; avoid calcium/iron within 4h
Differential Diagnosis
- Depression, CFS, anemia
- Nephrotic syndrome (edema)
- Lipid disorder (hypercholesterolemia)
- Hypopituitarism (secondary hypothyroidism)
Contraindications
- Untreated adrenal insufficiency: do NOT start levothyroxine before cortisol replacement (precipitates adrenal crisis)
- Calcium, iron, cholestyramine: reduce LT4 absorption (separate by 4h)
4οΈβ£ HYPERTHYROIDISM / GRAVES' DISEASE
Pathophysiology
Excess T3/T4 β hypermetabolism. Graves' = TSI (TSH receptor stimulating antibodies)
Age Group
Young to middle-aged adults; F:M = 7β10:1; can occur in pregnancy (Graves')
Clinical Findings
- Heat intolerance, weight loss despite good appetite, palpitations, tremor
- Tachycardia, atrial fibrillation, hypertension (widened pulse pressure)
- Exophthalmos (proptosis), lid lag, lid retraction β Graves' specific
- Pretibial myxedema, thyroid acropachy β Graves' specific
- Thyroid bruit, diffuse goiter
- Thyroid storm: HR >140, hyperpyrexia >40Β°C, confusion/coma β ICU emergency
Investigations
| Test | Finding |
|---|
| TSH | βββ (suppressed) |
| Free T4 / Free T3 | ββ |
| TSI (TSH receptor antibodies) | Positive in Graves' |
| Thyroid uptake scan | β Diffuse uptake (Graves'); focal hot nodule (toxic adenoma) |
| CBC | Neutropenia (if on antithyroid drugs) |
| LFTs | β (Graves' hepatopathy) |
Blood Count (CBC)
- RBC: Normocytic anemia (increased plasma volume effect)
- WBC: β Neutropenia (risk with propylthiouracil/methimazole β check BEFORE antithyroid therapy)
- Platelets: May be β (immune thrombocytopenia in Graves')
Treatment
| Option | Details |
|---|
| Antithyroid drugs | Methimazole (preferred) or PTU (preferred in 1st trimester); 12β18 month course; check CBC (agranulocytosis risk) |
| Radioiodine (RAI) ΒΉΒ³ΒΉI | Definitive; not in pregnancy/active ophthalmopathy |
| Surgery | Near-total thyroidectomy (large goiter, compressive symptoms, cancer concern) |
| Beta-blockers | Propranolol/atenolol for symptomatic control (tremor, palpitations) β use until euthyroid |
| Thyroid storm (ICU) | PTU + iodine (Lugol's, 1h after PTU) + propranolol IV + hydrocortisone + cooling + IV fluids |
Nutrition
- High-calorie, high-protein diet (hypermetabolic state)
- Avoid iodine-rich foods/supplements (seaweed, kelp) if on antithyroid therapy
- Calcium/vitamin D supplementation post-thyroidectomy
Contraindications
- Methimazole: teratogenic in 1st trimester (use PTU instead)
- RAI: absolute contraindication in pregnancy and breastfeeding
- Iodine (Lugol's): never give BEFORE antithyroid drugs (Jod-Basedow worsening)
ICU Indications
Thyroid storm, severe cardiac arrhythmia, heart failure
5οΈβ£ CUSHING'S SYNDROME
Pathophysiology
Chronic excess cortisol: ACTH-dependent (pituitary adenoma = Cushing's disease 70%; ectopic ACTH) or ACTH-independent (adrenal adenoma/carcinoma, exogenous steroids)
Age Group
Adults 20β50 years; F>M; exogenous (iatrogenic) = most common cause overall
Clinical Findings
- Central obesity (buffalo hump, moon face, supraclavicular fat pads)
- Purple striae >1 cm width, thin skin, easy bruising
- Proximal muscle weakness, osteoporosis (fractures)
- Hypertension, hyperglycemia/T2DM, hypokalemia
- Hirsutism (women), menstrual irregularity, erectile dysfunction
- Depression, psychosis, insomnia
Investigations
| Test | Finding |
|---|
| 24-hr urine free cortisol | β (>3x upper limit of normal) |
| Late-night salivary cortisol | β (loss of diurnal rhythm) |
| Overnight 1mg dexamethasone suppression | No suppression (cortisol >1.8 mcg/dL) |
| ACTH level | β (ACTH-dependent) vs β (adrenal) |
| Pituitary MRI | Microadenoma (Cushing's disease) |
| High-dose DST (8mg) | Suppression in pituitary; NO suppression in ectopic |
| CRH stimulation | β in pituitary source |
| Adrenal CT | Adenoma or hyperplasia |
Blood Count (CBC)
- RBC: β Polycythemia (cortisol stimulates erythropoiesis)
- WBC: β Leukocytosis; neutrophilia + lymphopenia + eosinopenia (classic cortisol effect)
- Platelets: Normal or elevated
Treatment
| Cause | Treatment |
|---|
| Pituitary (Cushing's disease) | Transsphenoidal surgery (TSS); pasireotide/cabergoline if residual |
| Adrenal adenoma | Laparoscopic adrenalectomy |
| Ectopic ACTH | Treat primary tumor; bilateral adrenalectomy if source not found |
| Exogenous | Gradual steroid taper (never abrupt) |
| Medical bridge | Metyrapone, ketoconazole, mitotane, mifepristone |
Nutrition
- Low-sodium, low-calorie diet
- High calcium + vitamin D (counter osteoporosis)
- High protein (counter muscle wasting)
Differential Diagnosis
- Pseudo-Cushing's (depression, alcoholism, obesity)
- Metabolic syndrome
- PCOS (hirsutism, weight gain)
- Adrenal carcinoma
Contraindications
- Ketoconazole: hepatotoxicity risk; avoid with hepatic impairment
- Mitotane: teratogenic; contraception required
6οΈβ£ ADDISON'S DISEASE (PRIMARY ADRENAL INSUFFICIENCY)
Pathophysiology
Destruction/suppression of adrenal cortex β β cortisol + β aldosterone (β ACTH, β MSH β hyperpigmentation)
Age Group
Any age; autoimmune form peaks 30β50 years; tuberculosis-related (developing countries)
Clinical Findings
- Fatigue, weight loss, anorexia, nausea, vomiting
- Hyperpigmentation (sun-exposed areas, buccal mucosa, skin creases, scars)
- Hypotension (especially orthostatic), salt craving
- Adrenal crisis (Addisonian crisis): Severe hypotension/shock, vomiting, abdominal pain, fever, altered consciousness β ICU EMERGENCY
Investigations
| Test | Finding |
|---|
| Serum cortisol (8 AM) | <3 mcg/dL (diagnostic); <18 mcg/dL (suspicious) |
| ACTH stimulation test (250 mcg) | No rise in cortisol (peak <18 mcg/dL) |
| ACTH level | βββ (primary) |
| NaβΊ | β Hyponatremia |
| KβΊ | β Hyperkalemia |
| Glucose | β Hypoglycemia |
| Anti-adrenal antibodies (21-OH) | Positive (autoimmune) |
| Adrenal CT | Atrophy (autoimmune); calcification (TB); hemorrhage |
| DHEA-S | β |
Blood Count (CBC)
- RBC: β Normocytic anemia
- WBC: β Lymphocytosis + eosinophilia (classic β opposite of cortisol excess)
- Platelets: Normal
Treatment
| Setting | Treatment |
|---|
| OPD (chronic) | Hydrocortisone 15β20 mg/day (AM/PM split) + fludrocortisone 0.05β0.2 mg/day (mineralocorticoid) |
| Adrenal crisis (ICU) | IV hydrocortisone 100 mg bolus then 50β100 mg q6h β IV 0.9% NaCl 1L rapid β glucose correction β treat precipitant |
| Stress dosing | Double/triple hydrocortisone during illness, surgery, injury |
| Secondary AI | Hydrocortisone only (no fludrocortisone needed) |
Nutrition
- Liberal salt diet (especially in hot weather/exercise)
- High-carbohydrate snacks to prevent hypoglycemia
Differential Diagnosis
- Septic shock (no hyperpigmentation, normal ACTH)
- Secondary adrenal insufficiency (pituitary; no hyperpigmentation; βACTH)
- Hyponatremia from other causes (SIADH, hypothyroidism)
Contraindications
- Abrupt steroid discontinuation: never β precipitates adrenal crisis
- Rifampicin/anticonvulsants: accelerate cortisol metabolism (increase dose)
7οΈβ£ CONGENITAL HYPOTHYROIDISM
Pathophysiology
Absent/ectopic/dyshormonogenic thyroid β neonatal T4 deficiency β impaired brain development
Age Group
Neonates (incidence 1:2,000β4,000); F>M
Clinical Findings
- At birth: often normal (maternal T4 protective)
- Week 2β4: prolonged neonatal jaundice, poor feeding, hypotonia ("floppy baby"), hoarse cry, large fontanelle, macroglossia, umbilical hernia, mottled/dry skin, hypothermia
- Untreated β Cretinism: Intellectual disability, short stature, deaf-mutism
Investigations
| Test | Finding |
|---|
| Newborn screening (heel-prick) | β TSH or β T4 |
| Confirmatory serum TSH + Free T4 | βTSH, βFT4 |
| Thyroid ultrasound | Absence, hypoplasia, ectopia |
| Thyroid radionuclide scan | Confirms ectopia/agenesis |
| Bone age X-ray | Delayed ossification |
Blood Count (CBC)
- RBC: Macrocytic anemia common
- WBC: Usually normal
- Platelets: Normal
Treatment
- Levothyroxine 10β15 mcg/kg/day β start within 2 weeks of birth
- Monitoring: TSH/FT4 every 1β3 months in year 1; normalize TSH within 2 weeks
- Developmental follow-up essential
Nutrition
- Breastfeeding encouraged; avoid soy formula (blocks LT4 absorption)
- Adequate iodine in maternal diet during pregnancy
Contraindications
- Soy formula concurrent with LT4 β reduces absorption significantly
8οΈβ£ CONGENITAL ADRENAL HYPERPLASIA (CAH)
Pathophysiology
21-hydroxylase deficiency (95% of cases) β impaired cortisol + aldosterone synthesis β ACTH excess β androgen overproduction
Age Group
Neonates (salt-wasting crisis); virilizing form presents later in childhood; non-classic in adolescence/adulthood
Clinical Findings
- Salt-wasting (neonatal): Vomiting, poor feeding, dehydration, hyponatremia, hyperkalemia, shock (life-threatening Week 1β3)
- Female virilization: Ambiguous genitalia at birth (clitoromegaly, labial fusion)
- Males: Normal genitalia but early pubic hair, rapid growth β short stature
- Non-classic (adolescent/adult): Hirsutism, irregular menses, acne, early pubic hair
Investigations
| Test | Finding |
|---|
| 17-hydroxyprogesterone (17-OHP) | ββ (>10,000 ng/dL in classic) |
| Newborn screen | β17-OHP |
| ACTH stimulation | Exaggerated 17-OHP rise |
| Electrolytes | βNaβΊ, βKβΊ (salt-wasting) |
| Androstenedione / DHEA-S | β |
| CYP21A2 gene mutation | Confirms diagnosis |
| Bone age | Advanced |
Blood Count (CBC)
- RBC: Normal or β (Addisonian anemia component)
- WBC: β In acute salt-wasting crisis (stress response)
- Platelets: Normal
Treatment
| Form | Treatment |
|---|
| Salt-wasting crisis (NICU) | IV 0.9% NaCl + glucose + IV hydrocortisone 25 mg/mΒ² bolus |
| Chronic | Hydrocortisone 10β15 mg/mΒ²/day (3 doses) + fludrocortisone 0.05β0.2 mg/day |
| Non-classic | Low-dose hydrocortisone or prednisone (if symptomatic) |
| Surgery | Feminizing genitoplasty in virilized females (timing debated) |
| Stress dosing | 3Γ hydrocortisone during illness/surgery |
9οΈβ£ DIABETES INSIPIDUS (DI)
Pathophysiology
- Central DI: βADH production (pituitary/hypothalamus damage)
- Nephrogenic DI: Renal resistance to ADH
- Result: Massive dilute urine output β hypernatremia
Age Group
Any age; central DI: head trauma/surgery/tumors; nephrogenic: lithium use, genetic (infants)
Clinical Findings
- Polyuria: 3β20 L/day of dilute urine
- Polydipsia (if thirst intact) β prevents hypernatremia
- Hypernatremia/dehydration if unable to access water (unconscious, infants)
- Nocturia, fatigue
Investigations
| Test | Finding |
|---|
| Urine osmolality | <300 mOsm/kg (inappropriately dilute) |
| Serum osmolality | β >295 mOsm/kg |
| Serum sodium | β Hypernatremia |
| Water deprivation test | No urine concentration |
| Desmopressin (DDAVP) challenge | Urine concentrates β Central DI; No response β Nephrogenic DI |
| Copeptin / plasma ADH | β (central); Normal/β (nephrogenic) |
| MRI pituitary | Loss of posterior pituitary "bright spot" (central DI) |
Blood Count (CBC)
- RBC: β Hemoconcentration in dehydration
- WBC: Normal
- Platelets: Normal
Treatment
| Type | Treatment |
|---|
| Central DI | Desmopressin (DDAVP) intranasal/oral/IV; treat underlying cause |
| Nephrogenic DI | Low-sodium/low-protein diet; thiazide diuretics; indomethacin; discontinue lithium if possible |
| ICU/Acute | Gradual correction of hypernatremia (max 10 mEq/L/day); IV hypotonic fluids |
| Lithium-induced | Amiloride (protective) |
π SYNDROME OF INAPPROPRIATE ADH (SIADH)
Pathophysiology
Excess ADH β water retention β dilutional hyponatremia (euvolemic)
Age Group
Adults, elderly; post-neurosurgery, pneumonia, malignancy (small-cell lung cancer)
Clinical Findings
- Mild: headache, nausea, fatigue, confusion
- Severe (NaβΊ <120): seizures, coma, respiratory arrest
- No edema (euvolemic, not hypovolemic)
Investigations
| Test | Finding |
|---|
| Serum NaβΊ | β <135 mEq/L |
| Serum osmolality | β <275 mOsm/kg |
| Urine NaβΊ | β >20 mEq/L |
| Urine osmolality | β >100 mOsm/kg (inappropriately concentrated) |
| TSH / cortisol | Normal (exclude hypothyroidism/adrenal insufficiency) |
| CXR / CT chest | Exclude malignancy/pneumonia |
Blood Count (CBC)
- RBC: β Dilutional (pseudoanemia)
- WBC: Depends on underlying cause
- Platelets: Normal or β (dilutional)
Treatment
| Severity | Treatment |
|---|
| Mild (NaβΊ 125β135) | Fluid restriction 800β1000 mL/day; treat underlying cause |
| Moderate | Urea 15β30g/day orally; vaptans (tolvaptan) |
| Severe/Symptomatic (ICU) | 3% hypertonic saline (1β2 mL/kg/hr) β correct NaβΊ max 10β12 mEq/L in 24h (avoid osmotic demyelination) |
Contraindications
- Rapid NaβΊ correction >12 mEq/L/day β osmotic demyelination syndrome (ODS)
1οΈβ£1οΈβ£ ACROMEGALY
Pathophysiology
Pituitary GH-secreting adenoma β βGH β βIGF-1 β acral/soft-tissue overgrowth (post-epiphyseal fusion = acromegaly; pre-fusion = gigantism)
Age Group
Adults 30β50 years (mean delay in diagnosis ~10 years)
Clinical Findings
- Enlargement of hands, feet, jaw (prognathism), nose, tongue
- Frontal bossing, widened teeth spacing
- Coarsening facial features, skin thickening
- Hyperhidrosis, oily skin
- Carpal tunnel syndrome, arthropathy
- Hypertension, T2DM, sleep apnea
- Visual field defects (bitemporal hemianopia β chiasm compression)
- Headache, fatigue
Investigations
| Test | Finding |
|---|
| IGF-1 | ββ (best screening test) |
| GH after 75g glucose (OGTT) | Fails to suppress to <1 ng/mL |
| Pituitary MRI | Macroadenoma (>1cm, 75%) |
| Fasting glucose / HbA1c | Elevated (GH-induced insulin resistance) |
| Colonoscopy | β Colorectal polyp/cancer risk |
| Echocardiogram | LVH, cardiomyopathy |
| Sleep study | Obstructive sleep apnea |
Blood Count (CBC)
- RBC: β Polycythemia (GH stimulates erythropoiesis)
- WBC: Normal
- Platelets: Normal
Treatment
| Modality | Details |
|---|
| Surgery | Transsphenoidal surgery (first-line; cure rate ~80% for microadenoma) |
| Somatostatin analogues | Octreotide LAR, lanreotide (medical bridge or adjunct) |
| GH receptor antagonist | Pegvisomant (IGF-1 normalisation; not GH) |
| Dopamine agonist | Cabergoline (if mixed GH/PRL tumor) |
| Radiotherapy | Stereotactic radiosurgery (slow IGF-1 normalisation over years) |
Nutrition
- Low glycemic index diet (insulin resistance management)
- Calcium + Vitamin D (osteoporosis risk)
1οΈβ£2οΈβ£ GIGANTISM
Pathophysiology
GH excess (pituitary adenoma, McCune-Albright syndrome, MEN1, X-LAG syndrome) before epiphyseal closure β excessive linear growth
Age Group
Children and adolescents (before growth plate fusion)
Clinical Findings
- Height >3 SD above mean for age
- Large hands/feet, headache, visual changes
- Delayed puberty (if gonadotropin co-affected)
- Same metabolic features as acromegaly (hyperglycemia, hypertension)
- Gigantism + acral features if diagnosed late
Investigations
Same as acromegaly + bone age X-ray (open epiphyses)
Blood Count (CBC)
- RBC: β (as acromegaly)
- WBC/Platelets: Normal
Treatment
Same as acromegaly; somatostatin analogues crucial in pediatric patients to preserve growth plates; surgery after puberty if possible
1οΈβ£3οΈβ£ PHEOCHROMOCYTOMA
Pathophysiology
Catecholamine (epinephrine, norepinephrine, dopamine)-secreting tumor of adrenal medulla (90%) or extra-adrenal paraganglioma
Age Group
Adults 30β50 years; 10% in children; 10% malignant; 10% bilateral; 10% extra-adrenal (rule of 10s)
Associated with MEN2A/2B, VHL, NF1, SDH mutations
Clinical Findings
- Classic triad: Episodic hypertension + headache + diaphoresis ("spells")
- Palpitations, pallor, anxiety, tremor
- Hypertensive crisis provoked by surgery, contrast, stress, drugs (TCA, metoclopramide)
- Sustained hypertension (50%) or paroxysmal (50%)
- Weight loss, hyperglycemia
Investigations
| Test | Finding |
|---|
| 24-hr urine metanephrines + catecholamines | β (sensitivity 98%) |
| Plasma free metanephrines | β (best initial test) |
| CT/MRI adrenal | Adrenal mass (>3 cm, heterogeneous, high T2) |
| ΒΉΒ²Β³I-MIBG scan | Functional uptake (localisation/metastases) |
| DOTATATE PET | Superior for paraganglioma |
| Genetic testing | SDHx, VHL, RET, NF1 mutations |
Blood Count (CBC)
- RBC: β Polycythemia (EPO stimulation)
- WBC: β Stress leukocytosis during crisis
- Platelets: Normal
Treatment
| Phase | Treatment |
|---|
| Pre-op Ξ±-blockade | Phenoxybenzamine (non-selective Ξ±) 10β14 days minimum, THEN add Ξ²-blocker |
| Surgery | Laparoscopic adrenalectomy (minimally invasive preferred) |
| Hypertensive crisis (ICU) | IV phentolamine (5β10 mg bolus) or IV nicardipine/nitroprusside |
| Malignant | MIBG therapy, chemotherapy (CVD: cyclophosphamide+vincristine+dacarbazine), sunitinib |
Contraindications
- NEVER give Ξ²-blockers before Ξ±-blockade (paradoxical hypertension β unopposed Ξ±-vasoconstriction)
- Metoclopramide, TCA, dopamine antagonists: can precipitate crisis
1οΈβ£4οΈβ£ PRIMARY HYPERALDOSTERONISM (CONN'S SYNDROME)
Pathophysiology
Autonomous aldosterone secretion (unilateral adenoma 35%, bilateral hyperplasia 60%) β βNaβΊ retention, βKβΊ excretion β hypertension + hypokalemia
Age Group
Adults 30β60; accounts for ~10% of all hypertension (most undiagnosed)
Clinical Findings
- Resistant hypertension (refractory to 3+ drugs)
- Hypokalemia: muscle weakness, cramps, palpitations, polyuria/polydipsia (nephrogenic DI-like)
- Often asymptomatic (KβΊ may be normal in 50%)
- Headache, fatigue
Investigations
| Test | Finding |
|---|
| Aldosterone-to-renin ratio (ARR) | >30 (with aldosterone >15 ng/dL) β screening |
| Confirmatory: Fludrocortisone suppression / salt loading | Aldosterone not suppressed |
| Adrenal CT | Adenoma vs bilateral hyperplasia |
| Adrenal vein sampling (AVS) | Lateralisation (gold standard before surgery) |
| Serum KβΊ | β (not always) |
| Plasma renin | ββ (suppressed) |
Blood Count (CBC)
- RBC: Normal
- WBC: Normal
- Platelets: Normal
Treatment
| Type | Treatment |
|---|
| Unilateral adenoma | Laparoscopic adrenalectomy (curative in >50%) |
| Bilateral hyperplasia | Mineralocorticoid antagonist: spironolactone (first-line) or eplerenone (fewer anti-androgen side effects) |
| KβΊ replacement | Pre-op + until surgery |
Contraindications
- Spironolactone: contraindicated in CKD/hyperkalemia (eGFR <30), pregnancy
- ACE inhibitors/ARBs combined with spironolactone: hyperkalemia risk
1οΈβ£5οΈβ£ HYPOPARATHYROIDISM
Pathophysiology
βPTH β βserum CaΒ²βΊ + βserum phosphate β neuromuscular excitability
Age Group
Any age; most common post-thyroid/parathyroid surgery; autoimmune; DiGeorge syndrome (children)
Clinical Findings
- Tetany: Carpopedal spasm, perioral tingling, laryngospasm, bronchospasm
- Chvostek sign: Facial twitch on tapping CN VII
- Trousseau sign: Carpal spasm after BP cuff inflation
- Seizures (hypocalcemic), QTc prolongation β arrhythmia
- Cataracts, calcification of basal ganglia, dry skin, brittle nails
Investigations
| Test | Finding |
|---|
| Serum CaΒ²βΊ | β <8.5 mg/dL (total); iCa β |
| Serum Phosphate | β |
| PTH | β or undetectable |
| Vitamin D (25-OH) | Check level |
| ECG | Prolonged QTc |
| Urine CaΒ²βΊ | Normal (distinguish from pseudohypoparathyroidism) |
Blood Count (CBC)
- RBC: Normal
- WBC: Lymphopenia (DiGeorge syndrome β thymic aplasia)
- Platelets: Normal
Treatment
| Setting | Treatment |
|---|
| Acute/Severe (ICU) | IV calcium gluconate 10% (10 mL over 10 min) β continuous infusion; cardiac monitor |
| OPD (chronic) | Oral calcium carbonate 1β3g/day + active Vitamin D (calcitriol 0.25β2 mcg/day) |
| Definitive | Recombinant PTH (teriparatide/Natpara) for refractory cases |
Contraindications
- Thiazide diuretics promote CaΒ²βΊ reabsorption β potentially useful
- Loop diuretics: worsen hypocalcemia β avoid
- IV calcium too rapidly: cardiac arrest risk (bradycardia/asystole)
1οΈβ£6οΈβ£ PRIMARY HYPERPARATHYROIDISM
Pathophysiology
Autonomous PTH secretion (adenoma 80%, hyperplasia 15%, carcinoma <1%) β hypercalcemia
Age Group
Adults >50; F>M (3:1); associated with MEN1, MEN2A, lithium use
Clinical Findings
- Often asymptomatic (incidental hypercalcemia)
- Stones (nephrolithiasis), Bones (osteitis fibrosa cystica, fractures), Groans (GI: constipation, PUD, pancreatitis), Psychic moans (depression, cognitive impairment)
- Hypercalcemic crisis (CaΒ²βΊ >14 mg/dL): profound weakness, confusion, cardiac arrhythmia, coma β ICU
Investigations
| Test | Finding |
|---|
| Serum CaΒ²βΊ | β |
| PTH | β (inappropriate for hypercalcemia) |
| Phosphate | β |
| Alkaline phosphatase | β (bone involvement) |
| 24-hr urine CaΒ²βΊ | β |
| Technetium sestamibi scan | Localizes adenoma |
| DEXA bone scan | Osteoporosis/osteopenia |
| Renal USS | Nephrolithiasis |
Blood Count (CBC)
- RBC: β (mild polycythemia) or normal
- WBC: Normal
- Platelets: Normal
Treatment
| Indication | Treatment |
|---|
| Symptomatic / CaΒ²βΊ >1mg/dL above normal / age <50 / T-score <-2.5 | Parathyroidectomy (surgery) |
| Asymptomatic surveillance | Monitoring CaΒ²βΊ, PTH, DEXA, renal function annually |
| Medical | Cinacalcet (calcimimetic) β reduces PTH; bisphosphonates for osteoporosis |
| Hypercalcemic crisis (ICU) | IV 0.9% NaCl 200β300 mL/hr β furosemide β IV bisphosphonate (zoledronic acid) β calcitonin β dialysis if refractory |
Contraindications
- Thiazides: worsen hypercalcemia β avoid
- Lithium: induces/worsens hyperparathyroidism
1οΈβ£7οΈβ£ POLYCYSTIC OVARY SYNDROME (PCOS)
Pathophysiology
LH/FSH imbalance β βLH β βandrogen production by ovarian theca cells + insulin resistance β anovulation, hyperandrogenism, polycystic ovaries
Age Group
Reproductive-age females (15β44 years); most common endocrinopathy in women of reproductive age
Clinical Findings (Rotterdam criteria: 2 of 3)
- Oligo/anovulation (irregular periods, infertility)
- Clinical/biochemical hyperandrogenism (hirsutism, acne, alopecia, βtestosterone)
- Polycystic ovaries on USS (β₯12 follicles per ovary or ovarian volume >10 mL)
- Metabolic: obesity, insulin resistance, T2DM risk, dyslipidemia
- Long-term: βendometrial cancer risk (anovulatory cycles β unopposed estrogen)
- Mood disorders, sleep apnea
Investigations
| Test | Finding |
|---|
| LH:FSH ratio | β (>2:1, supportive) |
| Total/free testosterone | β |
| DHEA-S | β (mild adrenal androgen) |
| 17-OHP (AM fasting) | Normal or mildly β (exclude CAH) |
| SHBG | β (increased free testosterone) |
| Fasting glucose + insulin (HOMA-IR) | Insulin resistance |
| Pelvic USS | β₯12 follicles, "pearl necklace" appearance |
| TSH, prolactin | Exclude hypothyroidism / hyperprolactinemia |
Blood Count (CBC)
- RBC: Normal or mild β (oligomenorrheic; less blood loss)
- WBC: Normal or mild β (low-grade inflammation)
- Platelets: Often β (chronic inflammation/metabolic syndrome association)
Treatment
| Goal | Treatment |
|---|
| Menstrual regulation | Combined OCP (estrogen-progestogen) |
| Hyperandrogenism | OCP + spironolactone (anti-androgen); topical eflornithine |
| Ovulation induction (fertility) | Letrozole (first-line); clomiphene; metformin |
| Insulin resistance | Metformin; lifestyle (weight loss 5β10% restores ovulation) |
| Metabolic | Low-carb diet, exercise, weight loss |
Nutrition
- Low glycemic index diet
- Weight loss reduces androgen levels and restores menstrual regularity
- Mediterranean diet (anti-inflammatory)
Contraindications
- Spironolactone: teratogenic (contraception mandatory); hyperkalemia if KβΊ abnormal
- OCP: avoid in migraine with aura, thrombophilia, smokers >35
1οΈβ£8οΈβ£ PRECOCIOUS PUBERTY
Pathophysiology
- Central (GnRH-dependent): Premature hypothalamic GnRH β LH/FSH β sex hormone activation; often idiopathic in girls
- Peripheral (GnRH-independent): Gonadotropin-independent sex hormone secretion (CAH, McCune-Albright, exogenous hormones, gonadal/adrenal tumor)
Age Group
Girls <8 years; Boys <9 years
Clinical Findings
Central: Thelarche, pubarche, menarche (girls); testicular enlargement, pubic hair (boys); advanced bone age; accelerated growth β early epiphyseal fusion β short adult stature
Peripheral: CafΓ©-au-lait spots + fibrous dysplasia (McCune-Albright); asymmetric bone changes
Investigations
| Test | Finding |
|---|
| Bone age X-ray | Advanced (>2 SD) |
| LH/FSH baseline | β (pubertal levels) in central PP |
| GnRH stimulation test | LH >5 IU/L post-stimulation = central PP |
| Estradiol / Testosterone | β |
| DHEA-S, 17-OHP | Elevated if adrenal cause |
| MRI brain | CNS tumor/hamartoma (especially boys) |
| Pelvic USS / Testicular USS | Gonadal tumor |
| Thyroid function (TSH/T4) | Severe hypothyroidism can cause precocious puberty |
Blood Count (CBC)
- RBC: β (androgens stimulate erythropoiesis in boys)
- WBC: Normal
- Platelets: Normal
Treatment
| Type | Treatment |
|---|
| Central PP | GnRH agonist (leuprolide, histrelin implant) β arrests puberty; restores adult height potential |
| CAH-related | Treat CAH (hydrocortisone) |
| Tumor-related | Surgery/chemo for gonadal/adrenal tumor |
| McCune-Albright | Aromatase inhibitors (letrozole) in girls |
1οΈβ£9οΈβ£ GROWTH HORMONE DEFICIENCY (GHD)
Pathophysiology
βGH from pituitary (congenital, perinatal insult, tumor, idiopathic) β βIGF-1 β reduced linear growth (children) + metabolic effects (adults)
Age Group
- Children: Short stature, delayed bone age
- Adults: Post-pituitary adenoma surgery/irradiation; metabolic syndrome phenotype
Clinical Findings
Children: Height <β2 SD (below 3rd percentile), slow growth velocity (<4 cm/year), chubby body, immature face, micropenis (boys, neonates), hypoglycemia (neonates)
Adults: Increased adiposity (central), reduced lean mass, fatigue, dyslipidemia, reduced bone density, decreased quality of life
Investigations
| Test | Finding |
|---|
| IGF-1 | β (best screening test) |
| GH stimulation test (insulin tolerance test or glucagon) | GH peak <3β10 ng/mL (criteria vary by assay/age) |
| MRI pituitary | Structural lesion / empty sella |
| Bone age X-ray | Delayed |
| IGF-BP3 | β |
| Other pituitary hormones | Assess for panhypopituitarism |
Blood Count (CBC)
- RBC: β Normocytic anemia (GH promotes erythropoiesis)
- WBC: Normal
- Platelets: Normal
Treatment
| Age | Treatment |
|---|
| Children | Recombinant GH (somatropin) 0.025β0.05 mg/kg/day SC; until final height reached |
| Adults | Lower-dose somatropin (0.1β0.4 mg/day) for metabolic benefits |
| Monitor | IGF-1 levels, blood glucose, height velocity, DEXA |
Contraindications
- GH therapy: contraindicated in active malignancy, proliferative diabetic retinopathy, closed epiphyses (children), Prader-Willi with severe obesity/sleep apnea (risk of sudden death)
- Titrate cautiously in diabetes (can worsen insulin resistance)
2οΈβ£0οΈβ£ PROLACTINOMA
Pathophysiology
Benign PRL-secreting pituitary adenoma β βprolactin β dopamine inhibition of GnRH β hypogonadism + galactorrhea
Age Group
Young women 20β40 (microadenoma common); men present later with macroadenoma (larger at diagnosis)
Clinical Findings
Women: Amenorrhea, galactorrhea, infertility, low libido, vaginal dryness (hypoestrogen)
Men: Erectile dysfunction, low libido, infertility, galactorrhea (rare), gynecomastia
Both (Macroadenoma >1cm): Headache, bitemporal hemianopia, cranial nerve palsy, hypopituitarism
Investigations
| Test | Finding |
|---|
| Serum prolactin | Microadenoma: 100β200 ng/mL; Macroadenoma: >200 ng/mL |
| Exclude physiological/drug causes | Pregnancy test, medication review (antipsychotics, metoclopramide, verapamil) |
| MRI pituitary with contrast | Adenoma visualization |
| Visual field testing | Bitemporal hemianopia if suprasellar extension |
| LH/FSH/testosterone/estradiol | β (hypogonadism) |
| TSH | Exclude hypothyroidism (β TRH stimulates PRL) |
Blood Count (CBC)
- RBC: β Normocytic anemia (estrogen deficiency in women; testosterone β in men)
- WBC: Normal
- Platelets: Normal
Treatment
| Indication | Treatment |
|---|
| First-line (medical) | Dopamine agonist: Cabergoline (0.5β2 mg twice weekly β superior efficacy/tolerability) or Bromocriptine |
| Surgical | Transsphenoidal surgery if: DA-resistant/intolerant, vision loss, emergency (apoplexy) |
| Radiotherapy | Reserved for refractory cases |
| Pregnancy | Bromocriptine preferred (more safety data); discontinue cabergoline once pregnant (controversial for macroadenomas) |
Contraindications
- Cabergoline: avoid in valvular heart disease (high dose fibrotic risk); use caution in psychiatric disorders
- Estrogen-only OCP in untreated prolactinoma: controversial (may stimulate growth)
π¬ CONSOLIDATED CBC / HEMATOLOGY SUMMARY
| Disease | RBC | WBC | Platelets | Key Pattern |
|---|
| T1DM (DKA) | Normal/β | β (stress/infection) | Normal | Leukocytosis in DKA |
| T2DM | β (late CKD) | Normal | Normal/β | |
| Hypothyroidism | β Macrocytic | Normal | May β | Macrocytic anemia |
| Hyperthyroidism | β (dilutional) | β Neutropenia (drugs) | May β | Drug-induced agranulocytosis risk |
| Cushing's | β Polycythemia | β Neutrophilia, β Lympho/Eosino | Normal/β | Classic cortisol leukogram |
| Addison's | β Normocytic | β Lymphocytosis + Eosinophilia | Normal | Opposite of Cushing's |
| Congenital Hypothyroidism | β Macrocytic | Normal | Normal | |
| CAH | Normal/β | β (crisis) | Normal | |
| Diabetes Insipidus | β (hemoconcentration) | Normal | Normal | |
| SIADH | β (dilutional) | Cause-dependent | β (dilutional) | |
| Acromegaly | β Polycythemia | Normal | Normal | |
| Gigantism | β | Normal | Normal | |
| Pheochromocytoma | β Polycythemia | β (crisis) | Normal | Paroxysmal |
| Conn's Syndrome | Normal | Normal | Normal | |
| Hypoparathyroidism | Normal | β (DiGeorge) | Normal | |
| Hyperparathyroidism | Normal/β | Normal | Normal | |
| PCOS | Normal/β | Normal/β | β | Inflammatory pattern |
| Precocious Puberty | β (androgens) | Normal | Normal | |
| GHD | β Normocytic | Normal | Normal | |
| Prolactinoma | β Normocytic | Normal | Normal | Hypogonadal anemia |
π₯ ICU vs OPD MANAGEMENT GUIDE
| Condition | OPD | ICU Trigger |
|---|
| T1DM | Routine insulin management, HbA1c monitoring | DKA (pH <7.3, bicarbonate <15, altered consciousness) |
| T2DM | Lifestyle + oral agents/insulin | HHS (glucose >600, osmolality >320, no ketones), severe hypoglycemia |
| Hypothyroidism | Levothyroxine titration | Myxedema coma (hypothermia, coma, bradycardia) |
| Hyperthyroidism | Antithyroid drugs, beta-blockers | Thyroid storm (HR>140, hyperpyrexia, coma) |
| Cushing's | Biochemical work-up, surgery scheduling | Adrenal crisis post-op, severe infection |
| Addison's | Steroid replacement, sick-day rules | Adrenal crisis (hypotension, shock, hyponatremia) |
| CAH | Hydrocortisone + fludrocortisone | Salt-wasting neonatal crisis |
| Diabetes Insipidus | DDAVP outpatient titration | Severe hypernatremia, unconscious patient |
| SIADH | Fluid restriction, treat cause | NaβΊ <120 with seizures/coma (hypertonic saline) |
| Pheochromocytoma | Alpha-blockade, surgery scheduling | Hypertensive crisis (phentolamine IV) |
| Hypoparathyroidism | Oral CaΒ²βΊ + calcitriol | Severe tetany, seizures, QTc prolongation (IV calcium) |
| Hyperparathyroidism | Surveillance or cinacalcet | Hypercalcemic crisis CaΒ²βΊ >14 mg/dL |
| Prolactinoma | Cabergoline | Pituitary apoplexy (hemorrhage into tumor) |
π₯ CONSOLIDATED NUTRITION GUIDE
| Disease | Key Nutritional Focus |
|---|
| T1DM / T2DM | Carbohydrate counting; low GI foods; fiber >25g/day; Mediterranean diet |
| Hypothyroidism | Adequate iodine; selenium (Hashimoto's); take LT4 before food |
| Hyperthyroidism | High-calorie/protein; avoid excess iodine; CaΒ²βΊ + Vit D post-surgery |
| Cushing's Syndrome | Low sodium; high CaΒ²βΊ + Vit D; high protein (anti-catabolic) |
| Addison's Disease | Liberal salt; high-carb snacks; extra salt in heat/exercise |
| CAH | Salt supplementation in salt-wasting form; balanced growth calories |
| Acromegaly | Low GI (insulin resistance); CaΒ²βΊ + Vit D |
| PCOS | Low GI; Mediterranean diet; weight loss (5β10%) |
| Hypoparathyroidism | High calcium diet (dairy); Vit D; low-phosphate diet |
| Hyperparathyroidism | Adequate (NOT restricted) calcium; hydration; low-oxalate diet |
| GHD | Adequate protein and calories for growth (children); balanced adult diet |
β οΈ KEY CONTRAINDICATIONS SUMMARY
| Drug/Treatment | Contraindicated In |
|---|
| Metformin | eGFR <30, IV contrast (hold 48h), T1DM monotherapy, liver failure |
| SGLT-2i | T1DM (euDKA), eGFR <20, recurrent UTI/genital fungal infections |
| GLP-1 agonists | Personal/family history medullary thyroid cancer, MEN2 |
| Methimazole | 1st trimester pregnancy (use PTU) |
| RAI (ΒΉΒ³ΒΉI) | Pregnancy, breastfeeding, active Graves' ophthalmopathy |
| Beta-blocker in pheo | Before alpha-blockade (paradoxical hypertension) |
| Loop diuretics | Hypoparathyroidism / hypocalcemia (worsens) |
| Thiazides | Hypercalcemia / hyperparathyroidism (worsens) |
| Rapid NaβΊ correction | SIADH (>12 mEq/L/day β osmotic demyelination syndrome) |
| Levothyroxine alone | Untreated adrenal insufficiency (precipitates adrenal crisis) |
| Spironolactone | CKD/hyperkalemia, pregnancy |
| GH therapy | Active malignancy, closed epiphyses, severe Prader-Willi |
| Cabergoline high-dose | Pre-existing valvular heart disease |
| IV calcium bolus fast | Cardiac arrest risk β always infuse slowly on monitor |
π DIFFERENTIAL DIAGNOSIS FLOWCHART
HYPERTENSION (resistant)
βββ + Hypokalemia β PRIMARY HYPERALDOSTERONISM (Conn's)
βββ + Spells, sweating, headache β PHEOCHROMOCYTOMA
βββ + Moon face, striae, obesity β CUSHING'S SYNDROME
βββ + Sleep apnea β ACROMEGALY
AMENORRHEA + GALACTORRHEA
βββ + β Prolactin + MRI adenoma β PROLACTINOMA
βββ + TSH β β HYPOTHYROIDISM
βββ + LH:FSH β + USS polycystic β PCOS
HYPOGLYCEMIA
βββ Neonatal + salt-wasting β CAH or ADDISON'S
βββ + Insulinoma features β Insulinoma (separate entity)
βββ + Poor feeding, hypotonia, neonate β CONGENITAL HYPOTHYROIDISM / GHD
POLYURIA + POLYDIPSIA
βββ Glucose β β DM (T1 or T2)
βββ Glucose normal + dilute urine + NaβΊ β β DIABETES INSIPIDUS
βββ Glucose normal + hypokalemia + HTN β CONN'S SYNDROME
βββ CaΒ²βΊ β β HYPERPARATHYROIDISM
TALL STATURE (child) + LARGE HANDS/FEET
βββ β IGF-1 + β GH β GIGANTISM
SHORT STATURE (child)
βββ β IGF-1 + β GH stimulation β GHD
βββ β TSH + β FT4 β HYPOTHYROIDISM
π DIAGNOSTIC FLOW SUMMARY (QUICK REFERENCE)
| Symptom/Sign | First Test | Confirms |
|---|
| Hyperglycemia, polyuria | Fasting glucose, HbA1c | DM type (C-peptide, autoantibodies) |
| Weight gain, cold intolerance | TSH | Hypothyroidism |
| Weight loss, tremor, palpitations | TSH (suppressed) + FT4 | Hyperthyroidism |
| Hyperpigmentation + hypotension | 8AM cortisol β ACTH stim | Addison's disease |
| Moon face + purple striae | 24h UFC β ACTH | Cushing's syndrome |
| Episodic HTN + headache + sweating | Plasma metanephrines | Pheochromocytoma |
| Resistant HTN + hypokalemia | Aldosterone:Renin ratio | Conn's syndrome |
| Tetany + perioral tingling | Serum calcium + PTH | Hypoparathyroidism |
| Hypercalcemia + kidney stones | Serum CaΒ²βΊ + PTH | Hyperparathyroidism |
| Amenorrhea + galactorrhea | Prolactin + MRI | Prolactinoma |
| Polycystic ovaries + hirsutism | LH/FSH + testosterone + USS | PCOS |
| Excessive height + large acral | IGF-1 + OGTT-GH | Gigantism/Acromegaly |
| Short stature + slow growth | IGF-1 + GH stimulation test | GHD |
| Early puberty in child | Bone age + GnRH stimulation | Precocious Puberty |
| Massive dilute polyuria (normal glucose) | Urine osmolality + water deprivation | Diabetes Insipidus |
| Hyponatremia + euvolemic | Urine NaβΊ + urine Osm | SIADH |
| Prolonged neonatal jaundice + floppy | TSH + FT4 neonatal screen | Congenital hypothyroidism |
| Neonatal salt-wasting + ambiguous genitalia | 17-OHP + electrolytes | CAH |
Sources: Goldman-Cecil Medicine; Costanzo Physiology 7e; Katzung's Basic & Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics; Tietz Textbook of Laboratory Medicine 7e; Miller's Anesthesia 10e; Sabiston Textbook of Surgery; Family Medicine 9e. Compiled April 2026.
---Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.